TRVI Trevi Therapeutics
- 2.920
- +0.010+0.34%
Trevi Therapeutics News
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8
B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6
Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $8
Trevi Therapeutics Price Target Maintained With a $21.00/Share by EF Hutton
Trevi Therapeutics Is Maintained at Buy by EF Hutton
Trevi Therapeutics Analyst Ratings
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6
Trevi Therapeutics Price Target Maintained With a $21.00/Share by EF Hutton
Trevi Therapeutics Is Maintained at Buy by EF Hutton
Trevi Therapeutics Analyst Ratings
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating
JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8
Leerink Partners Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $7
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $9
B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $6
EF Hutton Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $21
Trevi Therapeutics Price Target Maintained With a $21.00/Share by EF Hutton
Trevi Therapeutics Is Maintained at Buy by EF Hutton
Analysis
Price Target
No Data
No Data